Navigation Links
Arena Pharmaceuticals Announces Fourth Quarter and Full Year 2010 Financial Results and Reviews Recent Developments
Date:3/11/2011

al is uncertain; Arena's response to the complete response letter for the lorcaserin NDA may not be submitted when anticipated or the information provided in such response may not satisfy the FDA; the FDA may request other information prior to or after Arena resubmits the lorcaserin NDA or approval of the lorcaserin NDA; unexpected or unfavorable new data; risks related to commercializing new products; Arena's ability to obtain and defend its patents; the timing, success and cost of Arena's research and development programs; results of clinical trials and other studies are subject to different interpretations and may not be predictive of future results; clinical trials and other studies may not proceed at the time or in the manner Arena or others expect or at all; Arena's ability to obtain adequate funds; risks related to relying on collaborative agreements; the timing and receipt of payments and fees, if any, from collaborators; and satisfactory resolution of pending and any future litigation or other disagreements with others. Additional factors that could cause actual results to differ materially from those stated or implied by Arena's forward-looking statements are disclosed in Arena's filings with the Securities and Exchange Commission. These forward-looking statements represent Arena's judgment as of the time of this release. Arena disclaims any intent or obligation to update these forward-looking statements, other than as may be required under applicable law.Contact: Arena Pharmaceuticals, Inc.

Media Contact: Russo PartnersJack Lief

David Schull, PresidentPresident and CEO

david.schull@russopartnersllc.com858.717.2310Cindy McGeeManager, IR and Corporate Communications

Anthony J. Russo, Ph.D., CEO858.453.7200, ext. 1479

tony.russo@russopartnersllc.com212.845.4251www.arenapharm.com Arena Pharmaceuticals, Inc.Condensed Co
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Arena Pharmaceuticals to Present at Four Upcoming Investor Conferences
2. Arena Pharmaceuticals Announces Positive Phase 2 Clinical Trial Results of APD125 for the Treatment of Insomnia
3. Arena Pharmaceuticals Announces APD668 Initial Clinical Study Results Suggest Glucose-Dependent Insulinotropic Receptors May Improve Glucose Control in Patients With Type 2 Diabetes
4. Arena Pharmaceuticals Announces Positive Phase 1a Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis and Initiates Phase 1b Clinical Trial
5. Arena Pharmaceuticals Initiates Phase 2b Clinical Trial of APD125 for the Treatment of Insomnia
6. Arena Pharmaceuticals, Inc. Announces Initiation of Phase 1 Clinical Trial of Drug Candidate Under Partnership with Taisho Pharmaceutical Co., Ltd.
7. Arena Pharmaceuticals Presented Positive Phase 2a Clinical Trial Results of APD125 for the Treatment of Insomnia at 22nd Annual Meeting of the Associated Professional Sleep Societies
8. Arena Pharmaceuticals Announces Positive Phase 1b Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis
9. Critical Pharmaceuticals Enter Sustained Release hGH Arena
10. Arena Pharmaceuticals Announces Preliminary Results of Phase 2b Clinical Trial of APD125 for the Treatment of Insomnia
11. Arena Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Type 2 Diabetes Drug Candidate in Partnership with Ortho-McNeil-Janssen Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/2/2015)... SAN FRANCISCO , June 2, 2015  Nektar ... Texas MD Anderson Cancer Center today announced a research ... evaluate NKTR-214, a CD122-biased cytokine designed to preferentially stimulate ... cells found naturally in the body.  CD122, which is ... a key signaling receptor that is known to increase ...
(Date:6/2/2015)... , June 2, 2015 Northstar ... first television and multi-media commercial advertisement, which it ... to promote SNORenz®, the company,s top selling product. ... the company,s past success with television advertising. Previous ... but this, more modern version takes an entertainment-oriented ...
(Date:6/2/2015)... und MADRID , ... Mündliche Präsentation (Abstract   10503), vorgestellt ... Clinical Oncology    PharmaMar teilt ... ( Janssen) Daten der multizentrischen Phase-3-Studie ... Verbesserung beim progressionsfreien Überleben (progression-free survival, PFS) ...
Breaking Medicine Technology:Nektar and MD Anderson Cancer Center Announce Phase 1/2 Clinical Research Collaboration for NKTR-214, a CD122-Biased Immuno-Stimulatory Cytokine 2Nektar and MD Anderson Cancer Center Announce Phase 1/2 Clinical Research Collaboration for NKTR-214, a CD122-Biased Immuno-Stimulatory Cytokine 3Nektar and MD Anderson Cancer Center Announce Phase 1/2 Clinical Research Collaboration for NKTR-214, a CD122-Biased Immuno-Stimulatory Cytokine 4Nektar and MD Anderson Cancer Center Announce Phase 1/2 Clinical Research Collaboration for NKTR-214, a CD122-Biased Immuno-Stimulatory Cytokine 5Nektar and MD Anderson Cancer Center Announce Phase 1/2 Clinical Research Collaboration for NKTR-214, a CD122-Biased Immuno-Stimulatory Cytokine 6Northstar releases its direct response multi-media ad designed to be used in national television advertising campaigns 2PharmaMar gibt bekannt, Janssens Studie zeige, dass Trabectedin die Krankheitsbekämpfung bei Patienten mit fortgeschrittenem Weichgewebesarkom verbessert 2PharmaMar gibt bekannt, Janssens Studie zeige, dass Trabectedin die Krankheitsbekämpfung bei Patienten mit fortgeschrittenem Weichgewebesarkom verbessert 3PharmaMar gibt bekannt, Janssens Studie zeige, dass Trabectedin die Krankheitsbekämpfung bei Patienten mit fortgeschrittenem Weichgewebesarkom verbessert 4PharmaMar gibt bekannt, Janssens Studie zeige, dass Trabectedin die Krankheitsbekämpfung bei Patienten mit fortgeschrittenem Weichgewebesarkom verbessert 5PharmaMar gibt bekannt, Janssens Studie zeige, dass Trabectedin die Krankheitsbekämpfung bei Patienten mit fortgeschrittenem Weichgewebesarkom verbessert 6
... Ltd. (NYSE Amex: CPD ) announced that ... (Sun) have been extended until January 28, 2012 but ... which was originally set to expire in January 2010, ... and is being extended for an additional 1 year ...
... Pharmaceutical Company (NYSE: KVa/KVb) today announced the filing of its ... with the Securities and Exchange Commission.  As a result, the ... 2010 Form 10-K to enable its securities to continue trading ... is currently working on preparing and filing its quarterly reports ...
Cached Medicine Technology:Caraco Pharmaceutical Laboratories, Ltd. Announces Extension and Future Termination of Distribution Agreements with Sun Pharma 2Caraco Pharmaceutical Laboratories, Ltd. Announces Extension and Future Termination of Distribution Agreements with Sun Pharma 3K-V Pharmaceutical Company Announces Filing of Fiscal Year 2010 Annual Report on Form 10-K With the Securities and Exchange Commission 2K-V Pharmaceutical Company Announces Filing of Fiscal Year 2010 Annual Report on Form 10-K With the Securities and Exchange Commission 3K-V Pharmaceutical Company Announces Filing of Fiscal Year 2010 Annual Report on Form 10-K With the Securities and Exchange Commission 4K-V Pharmaceutical Company Announces Filing of Fiscal Year 2010 Annual Report on Form 10-K With the Securities and Exchange Commission 5K-V Pharmaceutical Company Announces Filing of Fiscal Year 2010 Annual Report on Form 10-K With the Securities and Exchange Commission 6K-V Pharmaceutical Company Announces Filing of Fiscal Year 2010 Annual Report on Form 10-K With the Securities and Exchange Commission 7K-V Pharmaceutical Company Announces Filing of Fiscal Year 2010 Annual Report on Form 10-K With the Securities and Exchange Commission 8
(Date:6/2/2015)... a popular online store selling celebrity inspired fashion products, ... dresses. The company carries more than 1000 styles of ... a wide variety of summer events like wedding and ... quality trendy special occasion dresses and accessories. ... and cotton. Their products feature a wide range of ...
(Date:6/2/2015)... June 02, 2015 First Choice ... emergency rooms in the United States, named Kenneth Alan ... – Jones Road facility. , “We are pleased ... Houston-Jones Road facility,” said Dr. James M. Muzzarelli, Executive ... Dr. Totz received his undergraduate degree from St. Edwards ...
(Date:6/2/2015)... 2015 Thermi, formerly ThermiAesthetics, a ... successfully transitioned into its new company headquarters in ... company’s continued rapid worldwide expansion and houses the ... 25 Thermi employees, including those of the warehousing, ... “As one of the fastest growing aesthetic companies ...
(Date:6/2/2015)... MA (PRWEB) June 02, 2015 Join us ... Anniversary Awareness Walk in Honor of Rhonda Martin , who ... members have since dedicated their resources to raising awareness and ... seeks to raise awareness in hopes that there will be ... , All are welcome and encouraged to join the ...
(Date:6/1/2015)... 2015 The National Association of ... as a 2015-2016 inductee into its VIP Woman of ... distinction for leadership in business. NAPW is the nation’s ... than 700,000 members and over 200 operating Local Chapters. ... honor,” said NAPW President Star Jones. “Job satisfaction is ...
Breaking Medicine News(10 mins):Health News:First Choice Emergency Room Announces Dr. Kenneth Alan Totz as New Medical Director of Houston – Jones Road Facility 2Health News:Thermi Moves to New Corporate Headquarters as Rapid Company Expansion Continues 2Health News:New Awareness Raising Event in Westwood, NJ to Benefit Renowned Brain Aneurysm Foundation 2Health News:National Association of Professional Women Inducts Miriam Wirski, Holistic Life Coach, Into its VIP Woman of the Year Circle 2
... Results of two new studies suggest that low-dose estrogen ... experiencing menopausal hot flushes and bleeding. The June issue ... as effective as high-dose estrogen in treating menopausal symptoms. ... irregular bleeding.// , ...
... brain imaging techniques, scientists have indicated the patterns in ... to be stored or deleted. The study was done ... (MIT) and reported to the American Association for the ... ,The researchers coupled a number of different brain parts ...
... Australian researchers have identified a gene which allows the ... drugs.Plasmodium,is a single-celled organism which is transmitted to ... historically evaded control efforts by building resistance to virtually ... is hoped that the new discovery will lead to ...
... treat nausea, and research at the University of Sydney ... studies have shown that the active ingredients in ginger ... ingredient of chilli peppers and capsicum, a known pain ... the body called the vanilloid receptor, which sits on ...
... the hair loss associated with drug treatment for cancer. ,This ... a frequent side effect of cancer therapy and is often ... lives.// ,Currently, there is no effective way to stop ... attempt to minimise hair loss is to fit patients with ...
... researchers at Peterson Medical College, a strategy was developed ... Immunodeficiency Virus (HIV) out of dormancy in the cellular ... Samoan rainforest tree, and appears to stimulate the virus, ... body's immune system to detect and attack it.// ...
Cached Medicine News:Health News:An effective pain killer, 2Health News:Breakthrough in cancer therapy 2Health News:Prostratin- Drug to eradicate HIV 2
Biocryl™ Acrylic Foldable Lens....
The STAAR ELASTIMIDE lens, combines the best of foldable lens technology with traditional design. This lens contains a cast-molded, silicone optic with modified Polyimide haptics....
... The Bausch & Lomb UV-Absorbing, Silicone Posterior ... for primary implantation for the visual correction ... age or older in whom the cataractous ... extraction methods. This device is intended to ...
... lenses are manufactured using the ... Perspex CQ UV PMMA material ... and single piece lenses. Unioptic ... both nonphaco and phaco styles. ...
Medicine Products: